National Immunobiological Company (State Corporation Rostech) together with Cipla Limited, a global pharmaceutical company, during SPIEF'16 signed memorandum of understanding on innovative antiviral medical products for HIV and hepatitis C treatment and on technology transfer and active pharmaceutical ingredients (API) manufacturing. New drugs production will help to change therapeutic regimens and substantially increase availability of drugs for Russian patients. By 2019 total market share for anti-HIV drugs will increase to 60 per cent.

Nacimbio CEO Nikolay Semenov and Chandru Chawla, head of Cipla New Ventures, signed the memorandum of understanding on technology transfer for manufacturing of anti-HIV drugs and drugs for hepatitis C treatment.

“Today patients undergoing anti-HIV treatment have to take a lot of drugs every day. Our preparations will meet the expectations of Russian patients and will solve this problem. In 2017 we will finalize construction and validation of the manufacturing plant together with Cipla Ltd., products will be commercially available in 2018. Total investment in the project will be over 2.8 billion roubles,” stated Nacimbio CEO Nikolay Semenov.

“Currently there is no technology for full-cycle manufacturing of HIV treatment drugs in Russia,” said Subhanu Saxena, MD & Global CEO, Cipla Ltd. “We are glad that, as a responsible partner together with Nacimbio we will be able to improve drug availability for patients and make our contribution to the fight against HIV.”